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CD8+T cells have the potential to inﬂuence the outcome of cancer pathogenesis, including
complete tumor eradication or selection of malignant tumor escape variants. The Simian
virus 40 largeT-antigen (Tag) oncoprotein promotes tumor formation inTag-transgenic mice
and also provides multiple target determinants (sites) for responding CD8+ T cells in
C57BL/6 (H-2b) mice. To understand the in vivo quantitative dynamics of CD8+ T cells
after encountering Tag, we constructed a dynamic model from in vivo-generated data to
simulate the interactions between Tag-expressing cells and CD8+ T cells in distinct sce-
narios including immunization of wild-type C57BL/6 mice and of Tag-transgenic mice that
develop various tumors. In these scenarios the model successfully reproduces the dynam-
ics of both theTag-expressing cells and antigen-speciﬁc CD8+T cell responses.The model
predicts that the tolerance of the site-speciﬁcT cells is dependent on their apoptosis rates
and that the net growth of CD8+ T cells is altered in transgenic mice. We experimen-
tally validate both predictions. Our results indicate that site-speciﬁc CD8+ T cells have
tissue-speciﬁc apoptosis rates affecting their tolerance to the tumor antigen. Moreover,
the model highlights differences in apoptosis rates that contribute to compromised CD8+
T cell responses and tumor progression, knowledge of which is essential for development
of cancer immunotherapy.
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INTRODUCTION
Tumors are masses of host cells containing both genetically unsta-
ble cancer cells and supporting host cells, including cells of the
immune system. Tumor progression causes destructive patho-
genesis within the host and ultimately death. Tumor antigens,
particularly those that are unique to the tumor, can elicit an
adaptive immune response (Qin and Blankenstein, 2000; Patel
and Chiplunkar, 2009; Xu et al., 2009; Behboudi et al., 2010). In
particular, CD8+ T cells (TCD8s) can eliminate continuously aris-
ing nascent transformed cells, inhibit carcinogenesis, and main-
tain cellular homeostasis under normal conditions; this process
is known as immunosurveillance (Dunn et al., 2002; Schreiber
et al., 2004). Tumors,nevertheless, can escape immunosurveillance
through both antigenic loss and the promotion of immunosup-
pression, which leads to their progression. The immune response
to cancer is often studied either by tumor implantation or by
inducing autochthonous tumor formation in speciﬁc tissues in
mice. Tumor development can be induced in transgenic mice by
expressing oncoproteins under tissue-speciﬁc promoters. Trans-
genic mice which develop autochthonous tumors are especially
interesting since the tumor antigens are often self antigens derived
from non-mutated cellular proteins and tumor formation occurs
over an extended period of time, reproducing some of the
immunological roadblocks which limit effective immunotherapy.
Dynamic models of tumor–immune interactions have pro-
vided insights into the processes leading to immune response
failure during tumor progression. Such models have been applied
to study the effect of immunotherapeutic approaches (Day et al.,
2006; Castiglione and Piccoli, 2007; Kirschner and Tsygvintsev,
2009) and to characterize the various stages of the immune
response to infection and cancer, with particular focus on TCD8s
(De Boer et al., 2003; Bocharov et al., 2004; Antia et al., 2005;
de Pillis et al., 2005). These models highlight the importance of
a variety of features of the immune response to tumors, includ-
ing the density of tumor antigen, the duration of the interaction
between MHCI-peptide complexes and the T cell receptor (TCR),
TCD8 activation rates, immunological memory, and recruitment
of precursor cells. Our study provides a unique perspective rela-
tive to previous studies, in that we focus on a comparative analysis
of T cell responses in tumor-bearing versus wild-type (WT) mice.
The Simian virus 40 (SV40) large T-antigen (Tag) is a potent
virus-encoded oncoprotein that can transform a variety of cell
types (Ahuja et al., 2005). The oncogenic activity of Tag stems
from its ability to inactivate tumor suppressor proteins (Rb and
p53) aswell as to initiate cell cycle progression (Butel andLednicky,
1999). Tag can induce responses by MHC-I-restricted TCD8s, as is
observed for other tumor antigens. Four unique Tag determinants
recognized by TCD8s have been deﬁned in C57BL/6 mice (sites I,
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II/III, IV, and V; Mylin et al., 2000; Tevethia and Schell, 2001). The
TCD8 response to these four determinants forms a quantitative
hierarchy in which site IV, for which the most T cells accumulate,
is immunodominant followed by subdominant responses to sites I
and II/III. The response to site V, however, is immunorecessive, as
responding TCD8s are only detected following immunization with
Tag variants lacking the three dominant determinants, or after site
V-speciﬁc immunization (Tanaka et al., 1989; Fu et al., 1998). The
expression of Tag as a self-antigen within Tag-transgenic mice can
lead to TCD8s unresponsiveness by mechanisms promoting both
central and peripheral tolerance (Tevethia and Schell, 2001).
We construct a dynamic model describing tumor progression,
elimination of tumor cells, TCD8 expansion, and decay in the con-
text of the TCD8 response to SV40 Tag.We developed this model to
describe the TCD8 response in both WT C57BL/6 mice respond-
ing to immunization, where Tag-expressing cells are eliminated,
and in mice that express Tag as a transgene, leading to the devel-
opment of autochthonous tumors and TCD8 tolerance. For the
purposes of this model we deﬁne tolerance as the absence of a
functional T cell response in the presence of tumor antigen. In
transgenic mice, site-speciﬁc TCD8s become tolerant at different
time points (Theobald et al., 1997; Morgan et al., 1998; Colella
et al., 2000; Nugent et al., 2000; Cordaro et al., 2002; Otahal et al.,
2006; Fujimura et al., 2010) and this characteristic behavior is not
seen when the WT mice encounter the Tag as a foreign antigen.
Thus, themodel parameterized to reproduce this observation gives
insights into the characteristics of TCD8s that are changed during
tumor development.
Our model quantitatively reproduces the TCD8 response to
immunization with Tag-transformed cells in WT mice (Pretell
et al., 1979; Mylin et al., 2000) and the qualitative behavior of the
TCD8 response in mice bearing Tag-induced pancreatic tumors
(Otahal et al., 2006), osteosarcoma (Schell et al., 2000), or brain
tumors (Schell et al., 1999). The model reveals strong constraints
on the proliferation rates and decay rates of TCD8s during tumor
formation. Additionally, the model gives insight into how the acti-
vation, proliferation, and apoptosis rates of TCD8s impact the
expansion and contraction phase during the site-speciﬁc immune
response in normalmice, aswell as during tissue-speciﬁc responses
and development of tolerance.Our results indicate that though the
inherent characteristics of the site-speciﬁc T cell clones are differ-
ent, the overall TCD8 response dynamics are surprisingly similar
when encountering antigen in different tissues. We predict and
experimentally validate inequalities in the activation and decay
rates of the TCD8 responding to unique determinants.We also the-
oretically predict the rate constants leading to tumor formation,
the apoptosis rates of different TCD8 clones, the peaks of TCD8
activity in various tumor models and the mechanism of tolerance.
MATERIALS AND METHODS
DYNAMIC MODEL
Our model describes the growth of tumor by modeling the Tag-
expressing tumor/malignant cells (M ) and their removal by site I-,
II/III, IV-, andV-speciﬁc TCD8s (Ti;Figure 1). The basicmodel has
ﬁve ordinary differential equations and assumes that the cells form
well mixed populations. Since the dynamics after tumor clearance
are not considered in the current study, the memory T cell state is
FIGURE 1 |The interactions betweenTag-expressing cells (M) andTCD8s
and the parameters modeling the dynamics are depicted. Edges
represent activating (black arrows), inhibiting (blunt segments), and
tumor-induced (red arrows) interactions, f represents a Michaelis–Menten
function.
not modeled. The site-speciﬁc TCD8s are initially activated against
the tumor cells and are subsequently suppressed by the increas-
ing tumor size in addition to their apoptosis. Tag-expressing cells
exponentially proliferate at rate r which was estimated from the
initial growth phase of the tumors (see e.g., Mallet and De Pillis,
2006). The four site-speciﬁc TCD8s are assumed to kill tumor cells
(M ) at the same rate b; however, b is modulated by a Michaelis–
Menten function such that the rate of killing of tumor cells
stabilizes when the tumor size increases above β (Figure A1 in
Appendix).
Tag-expressing cells present four determinants I, II/III, IV, and
V that are recognized by MHCI molecules. MHCI-peptide com-
plexes are then recognized by TCR, which leads to the differenti-
ation of naive cells and subsequently the recruitment of TCD8s to
the tumor site. In the model, Tag-expressing cells induce a propor-
tion ni of competent site-speciﬁc TCD8s at a rate proportional to c.
Based on our recent experimental results (T. Schell, unpublished)
a 0.3/1/4 ratio for siteV/I/IVTCD8 activation fromnaïve T cells was
used to determine ni. Since the experimental observations could
be reproduced by using the same value of the proliferation rate c,
it was kept the same for all site-speciﬁc TCD8s. Thus nic represents
the activation rate of TCD8s from precursor cells and c represents
the proliferation of TCD8s. TCD8s undergo natural death at rate wi
which is different for the four determinants. The immunogenicity
of the determinants is decided by the site-speciﬁc activation and
decay rates. Tumor cells alter the microenvironment leading to
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the suppression of the TCD8 response (Ganss and Hanahan, 1998;
Gajewski et al., 2006). This suppression is modeled as a negative
modulation of the proliferation and activation rates in response
to a higher number of tumor cells. In the case of proliferation,
the effect is modeled with a Michaelis–Menten function which
sets proliferation to 0 for M = 0 and saturates at c for M >> σ.
The negative modulation of activation rates is modeled in the
opposite way, using a “repressive”Michaelis–Menten function: for
M << αi , activation occurs at a constant rate ni; for M >> αi , it
asymptotically approaches 0. In the absence of spatial compart-
ments, inhibition of the activation of new TCD8s represents the
suppression of the recruitment of the TCD8s at the site of tumor
which can occur by diffusible cytokines and chemokines produced
by the tumor cells.
In Tag-transgenic mice both central (Faas et al., 1987; Schell
et al., 1999; Colella et al., 2000; Zheng et al., 2002) and peripheral
tolerance (Ye et al., 1994; Schell et al., 2000; Cordaro et al., 2002;
Otahal et al., 2006) is observed in response to tumors. Tolerance is
modeled by the absence of functional TCD8s even in the presence
of the Tag-expressing cells. In central tolerance self-reactive T cells
are deleted during development in the thymus and there is no
recruitment at the site of tumors, which can be modeled by setting
the value of ni to 0.During peripheral tolerance self-reactive T cells
that escape to the periphery are maintained in a state of unrespon-
siveness or are deleted following activation. The gradual process of
peripheral tolerance is simulated by the tumor-induced suppres-
sion of TCD8s and by retraining the parameter values (explained
in Section “Results”).
Thus the dynamics of tumor cells (M ) and TCD8s speciﬁc for
site i (Ti) are given by
dM
dt
= rM − M
M + β
∑
i
bTi
dTi
dt
= c M
M + σ
(
ni
(
1 − M
M + αi
)
+ Ti
)
− wiTi ,
i ∈ [I, II/III, IV,V]
Note that though a constant source of site-speciﬁc precursor cells
(constant ni) was used in the model, their effective number is not
unlimited. In the WT model precursor cells stop differentiating
after the clearance of Tag-expressing cells, and in the tumor mod-
els activation of new TCD8s is inhibited by large tumors (so that
≈15 TCD8s are activated for 1000 tumor cells) and has a minimal
effect after the ﬁrst few days.
SIMULATED IMMUNIZATIONS
Immunization of transgenic mice was modeled, similarly to
Kirschner and Panetta (1998), by introducing a variable si that
follows the clearance dynamics of Tag-transformed cells injected
in WT mice by obeying the relation dsi/dt =−γSi. In the presence
of immunization, the T equation becomes
dTi
dt
=
[
(c + si) M
M + σ
] [
ni
(
1 − M
M + αi
)
+ Ti
]
− wiTi , i ∈ [I, II/III, IV,V]
NULLCLINE ANALYSIS
The nullcline analysis (Figures A2B–E in Appendix) is performed
to study the effect of parameter values on the temporal trajecto-
ries of the tumor cells and site-speciﬁc TCD8s (Figures 2B–E). The
nullcline analysis ﬁnds the equilibrium of the system when M and
Ti are in a steady state (dM/dt = dT/dt = 0). Considering a single
type of site-speciﬁc TCD8 for simplicity the equations become:
dM
dt
= 0 = rM − M
M + β bT
dT
dt
= 0 = c M
M + σ
(
n − n M
M + α + T
)
− wT
Solving these equations in terms of M and T yields
M = b
r
T − β
T = cnαM
(M + α) (M (w − c) + σw)
For the biologically accepted range of β (>0) in our model,
M =T = 0 is an unstable steady state. That is, for small num-
ber of tumor cells (M ) and TCD8s (T ), the value of tumor cells
FIGURE 2 |The response of site IV-specificTCD8s is shown in case
of (A) clearance, (B) non-zero steady state, (C) oscillations,
(D) tumor, and (E) uncontrolled response ofTag-expressing cells
(Tag-expressing cells shown in insets). In all cases the initial
condition is Tag-expressing cells= 100, site IV-speciﬁc TCD8 = 0. The
parameters r = 0.03/day, n = 1.8 (proportion), b = 0.5/day, c = 0.5/day,
w = 0.2/day, α= 40 cells, β= σ = 10 cells are used in all ﬁgures
with the following exceptions: (A) n = 0.3 (proportion), c = 0.29/day;
(B) β= σ = 50/day; (C) β= σ = 100/day; (D) c = 0.15/day;
(E) c = 0.21/day.
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will always increase in the tumor model. Additional biologically
signiﬁcant steady states are discussed in Section “Results.”
SUMMARY OF PUBLISHED EXPERIMENTAL DATA
We used published experimental data corresponding to TCD8s
derived from the spleen of WT C57BL/6 mice and three Tag-
transgenic mouse strains that develop distinct tumors. Data cor-
responding to splenic TCD8 responses were used since they are
available for all models and are representative for the systemic
response to the antigen. In the case of brain tumors, T cell accu-
mulation at the tumor site is correlated with spleen dynamics with
a time lag (Ryan and Schell, 2006).
Tag-speciﬁc TCD8 cells are measured by MHC tetramer staining
after encountering antigen which correlates with the number of
TCD8s that produce IFNγ upon peptide-speciﬁc in vitro stimula-
tion (Mylin et al., 2000). The published data and our own were
obtained from two independent sets of experiments that were
quantitatively different. In vivo model systems are often difﬁcult
to standardize. Hence, to account for lab-speciﬁc differences and
to align the data, we scaled the data from Mylin et al. (2000) by a
multiplicative factor that maximized the agreement.
The number of endogenous TCD8s in Tag-transgenic mice can
be very low and difﬁcult to detect. Hence induction of detectable
TCD8 responses can be stimulated by immunization of mice with
Tag-transformed cells expressing full-length WT Tag or Tag vari-
ants in which speciﬁc determinants have been eliminated by
mutagenesis. If immunization is not sufﬁcient to induce the T cell
response, due to deletion of T cell precursors during T cell devel-
opment, then splenocytes from WT mice, which contain naïve
TCD8s as well as other immune cell subsets, are injected (adoptively
transferred) into the Tag-transgenic mice. In such experiments,
saturating amounts of splenocytes were given to achieve maximal
T cell response.
CHEMICALS AND REAGENTS
All chemical reagents were purchased from Sigma-Aldrich
(St Louis, MO, USA). RPMI-1640 with Glutamax and fetal bovine
serum (FBS) were purchased from Invitrogen (Carlsbad, CA,
USA). Benzonase® Nuclease was purchased from EMD Chemicals
(San Diego, CA, USA). Annexin V Apoptosis Detection Kit, rat
anti-mouse CD16/CD32 Fc block, Cytoﬁx/Cytoperm, PermWash,
ﬂuorescein isothiocyanate (FITC), phycoerythrin (PE), allophyco-
cyanin (APC) or APC-Cy7-labeled anti-mouse CD8α, PE-labeled
anti-CD90.1, and FITC-labeled anti-5-bromo-2-deoxyuridine
(BrdU) antibody were purchased from BD Biosciences (San Jose,
CA, USA).
ANIMALS
Male and female C57BL/6 (H-2b) mice (4–6weeks old) were pur-
chased from The Jackson Laboratory (Bar Harbor, Maine) and
routinely used between the ages of 7 and 12weeks. SV11 (H-2b)
mice express full-length SV40 T Ag under the control of the SV40
promoter (Brinster et al., 1984). Line SV11 mice were maintained
by breeding hemizygous Tag transgene+ males with C57BL/6J
females and transgene positive animals identiﬁed as previously
described (Schell et al., 1999). TCR-IV transgenic mice express-
ing the TCRα and TCRβ chains speciﬁc for Tag site IV have been
previously described (Tatum et al., 2008) and were maintained by
breeding transgene positive males with B6.PL-Thy1a/CyJ females.
All mice were maintained in the animal facility at the Pennsylva-
nia State University College of Medicine, Hershey, PA, USA and
experiments were performed under guidelines approved by the
Institutional Animal Care and Use Committee.
IMMUNIZATION AND IDENTIFICATION OF SITE-SPECIFIC TCD8s
The B6/WT-19 cell line was derived previously by transformation
of B6 mouse embryo ﬁbroblasts with WT SV40 strain VA45-54
(Pretell et al., 1979; Tevethia et al., 1980). Production and char-
acterization of the Db/Tag site I (Db/I), Kb/Tag site IV (Kb/IV),
Db/inﬂuenza virus (Flu) nucleoprotein (NP) 366–374 (Db/Flu),
and Kb/HSV gB 498–505 (Kb/gB) PE-conjugated tetramers were
described previously (Mylin et al., 2000). For immunization,
5× 107 live B6/WT-19 cells were injected by the intraperitoneal
route. For adoptive transfer, SV11 or transgene negative mice
were injected intravenously with lymphocytes derived from TCR-
IV transgenic mice containing 5× 105 clonotypic site IV-speciﬁc
TCD8s. For tetramer staining, mouse spleens were harvested at the
indicated time points post immunization and processed to sin-
gle cell suspensions as previously described (Schell et al., 1999).
Erythrocyte-depleted splenocytes were washed twice in PBS–
FBS [PBS supplemented with 2% (vol/vol) FBS], resuspended at
2× 107 cells/ml in PBS–FBS, and incubated with rat anti-mouse
CD16/CD32 (33mg/ml) for 15min on ice. Following incuba-
tion, cells were washed once in PBS–FBS and resuspended in
ﬂuorescence-activated cell sorter (FACS) buffer [PBS–FBS sup-
plemented with 0.1% (wt/vol) sodium azide]. Aliquots containing
2× 106 cells were prepared and the appropriate MHC tetramer
plus anti-mouse CD8α antibody were added. Alternatively, TCR-
IV transgenic T cells were identiﬁed according to their surface
expression of CD90.1. In this case, cells were incubated with
anti-CD90.1 antibody at room temperature for 15min as well as
anti-CD8 and MHC tetramer to minimize non-speciﬁc staining.
Proliferation and apoptosis analysis focused on the population
of CD8+, Tetramer+, and CD90.1+ cells. Cells were then resus-
pended in FACS buffer and kept on ice or processed into apoptosis
assay prior to ﬂow cytometry.
APOPTOSIS ASSAY
2× 106 erythrocyte-depleted and MHC tetramer- and/or anti-
CD90.1-stained cells were incubated with conjugated Annexin
V and 7-AAD (1:100 dilution) in 100μl 1× Annexin V stain-
ing buffer for 15min at room temperature in the dark. Cells were
immediately assessedbyﬂowcytometry (BDFACSCalibur or FAC-
SCanto). At least 10000 events were collected in the live cell gate
and analyzed forAnnexinV and 7-AAD staining. AnnexinV nega-
tive,7-AADpositive cellswere considerednon-viable and excluded
from further analysis.
IN VIVO 5-BROMO-2-DEOXYURIDINE INCORPORATION ASSAY
Mice received a 1-mg dose of 1mg/ml BrdU solution (diluted
in PBS) 3 h before sacriﬁce by intraperitoneal injection at the
indicated times post immunization. Splenocytes were stained for
BrdU incorporation using a modiﬁed staining protocol (BD Bio-
sciences). Brieﬂy, 2× 106 splenocytes were stained with MHC
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tetramers and anti-mouse CD8α as described above. Cells were
then resuspended in 100μl of Cytoﬁx/Cytoperm (Becton Dickin-
son) and incubated for 30min at room temperature. The cells
were washed once with 1× PermWash, resuspended again in
100μl of Cytoﬁx/Cytoperm and incubated for 10min at room
temperature. Cells were washed again and resuspended in 100μl
Cytoﬁx/Cytoperm and incubated for 5min at room temperature.
After one wash, cells were incubated at 37˚C for 1 h with 20U Ben-
zonase nuclease in 100μl DPBS with 1mM MgCl2 and washed
once. Cells were then stained with 5μl of FITC-labeled anti-
BrdU antibody (eBioscience) in 40μl 1× PermWash for 20min
at room temperature. Cells were washed and then ﬁxed with
2% paraformaldehyde in PBS and analyzed by ﬂow cytometry
as above.
STATISTICAL TESTS
We performed the Welch two-sample t -test to assess whether the
ratio of the percentage of site IV-speciﬁc TCD8s proliferating in
WT to the similar percentage in SV11 mice is signiﬁcantly greater
than the similar ratio of the apoptotic cells. Three data points
were taken from the WT mice and four data points were taken
from SV11 mice. To construct the two groups for the statistical
test we used the percentage of proliferating and apoptotic cells in
all combinations in which WT values were in the numerator.
RESULTS
OVERVIEW OF TUMOR GROWTH (M ) AND TCD8 DYNAMICS
To study the characteristics of TCD8s modulation during tumor
development we developed a dynamic model of the interactions
between tumor cells (M ) and TCD8 (Ti) cells elicited in response
to the four unique determinants of Tag. In this section we dis-
cuss the repertoire of dynamical behaviors that emerged from the
model by describing the site IV-speciﬁc TCD8s in response to the
growing tumor (refer to Materials and Methods and Appendix for
details). Tag-expressing cells exponentially proliferate at rate r and
are killed by TCD8s at a rate that grows with tumor size, until the
tumor size becomes large compared to β (Figure A1 in Appendix);
after which the killing rate saturates to a rate b. Site IV-speciﬁc
TCD8s are activated against the tumor cells and proliferate but
their differentiation is subsequently suppressed by the increasing
tumor size and they also undergo natural death at rate w iv. Pro-
liferation and activation of TCD8s is suppressed by large tumors
and the suppression is modeled by Michaelis–Menten functions
parameterized by σ and αi respectively.
A repertoire of dynamical behaviors emerged from the model
including clearance of Tag-expressing cells, as in WT mice, or
tumor formation, as in Tag-transgenic mice. If Tag-expressing
cells are cleared, the T cell response contracts (Figure 2A). Tag-
expressing cells and T cells can also reach homeostasis (Figure 2B),
as is observed when mice are immunized prior to the develop-
ment of Tag-induced pancreatic tumors (Otahal et al., 2006).
In some cases, the number of TCD8 and Tag-expressing cells
ﬂuctuate for extended periods of time before reaching a steady
state (Figure 2C). If the TCD8 response is incapable of control-
ling the proliferating Tag-expressing cells, they increase exponen-
tially, and TCD8s either undergo tolerance, becoming unresponsive
(Figure 2D), or themselves expand continuously (Figure 2E).
Tounderstand the effect of theparameter values on thedynamic
behavior we performed a nullcline analysis (refer to Materials and
Methods andAppendix for details). The nullcline analysis provides
the long-term outcome resulting from the trajectories of change
in the concentrations of Tag-expressing cells and TCD8s. The
clearance scenario (Figure 2A; Figure A2A in Appendix) shows
increasing initial trajectories of Tag-expressing cells and TCD8s.
The increasing efﬁciency of TCD8-mediated killing of tumor cells
leads to ﬁrst a slowing down of the increase, and later a decrease
in tumor cell numbers (modeled by the value of M ). When the
number of Tag-expressing cells is below a certain threshold value
given by the nullcline analysis, TCD8s begin decreasing and even-
tually Tag-expressing cells and TCD8s are depleted. In the clearance
scenario the TCD8 response is maximized by setting the Michaelis–
Menten constant αi, which models the effect of tumor size on the
recruitment of new TCD8s, higher than the Tag-expressing cells.
Though lower values of αi are used in the tumormodels, increasing
αi cannot clear the tumor cells because it stimulates the differen-
tiation of effector cells from naïve T cells which is a linear process
and has a limited role in the control of exponential tumor growth
(Figure A1 in Appendix).
The nullcline analysis identiﬁed the salient parameters
that drive the system from one behavior type to another
(Figures 2B–E). Unlike in the clearance scenario in which tumor
cells are cleared, a larger value of Michaelis–Menten constants β
and/or σ, which model the effect of tumor size on the TCD8 activ-
ity, launch a protective TCD8 response characterized by a steady
state like behavior (Figure 2B; Figure A2B in Appendix). Further
increase in theseMichaelis–Menten constants (β and/or σ) leads to
extended oscillations of TCD8s and tumor cells (Figures 2C and 3;
Figure A2C in Appendix). As expected, decreased tumor growth
(lower r) and increased TCD8-mediated killing (b) (Figure 2E;
Figure A2E in Appendix) pushes the system toward tumor clear-
ance. The extreme cases when r < 0 are not relevant in the systems
that lead to tumor formation. In the following sectionswe consider
the dynamics of all the determinants in which case site-speciﬁc
TCD8 apoptosis rates and inhibition by tumor cells lead to the
characteristic TCD8 response against each determinant.
Though various parameters can affect the fate of the tumors
and consequently the TCD8 response, only the net growth of TCD8s,
described by the difference between the rate of activation (c) and
cell death (wi), decides the tolerance behavior (unresponsiveness
of the TCD8 cells). Decrease in the net growth transitions the sys-
tem from a clearance state (if c −wi is positive and large) observed
in WT mice to a tumor state observed in transgenic mice (if c −wi
is negative; see Figure 2D; Figure A2D in Appendix). Thus to
reproduce the tolerance of TCD8s observed in Tag-transgenic mice
wi is assumed to be greater than c in all tumor models. Our para-
meter analysis (Figure A3 in Appendix) indicates a large deviation
from the experimental results when the above condition on the
net growth of TCD8s is not implemented.
TCD8 NET GROWTH AND TOLERANCE
The TCD8 response to Tag inWTmice and in transgenicmice bear-
ing tumors provides two unique immunological environments
which are modeled by assuming positive and negative net growth
(c −wi) of TCD8s inWT and transgenic mice respectively. The fact
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that the TCD8 response is strong in WT mice but is undetectable
in transgenic mice (Schell et al., 2000; Otahal et al., 2006) lends
support to this assumption. The early expression of antigen in
Tag-transgenic mice might lead to a lower rate of expansion (c)
of TCD8s, allowing tumors to grow. Indeed, it is experimentally
observed that high amounts of antigen reduce the proliferation of
TCD8s during tolerance (Ganss and Hanahan, 1998).
To validate our hypothesis of the positive versus negative net
growth of TCD8s in WT versus transgenic mice we experimen-
tally assessed proliferation and apoptosis of TCD8s in both WT
mice and Tag-transgenic mice bearing brain tumors (Schell et al.,
1999). It is difﬁcult to obtain the absolute value of the rate of acti-
vation (c) and the rate of apoptosis (wi) through experimentation,
which renders it improper to directly compare the experimental
values.However,we noticed that if the net growth is positive inWT
(wWT < cWT) and negative in transgenic mice (wTumor > cTumor),
it implies that for a speciﬁc TCD8 clone, the ratio of proliferation
rates in WT to transgenic mice is greater than the similar ratio
of apoptosis rates [(cWT/cTumor)> (wWT/wTumor)]. The converse
implication is satisﬁed if the rates of T cell proliferation are
comparable in WT and tumor-bearing mice. To test this relation-
ship, we utilized TCD8s from TCR transgenic mouse line TCR-IV
in which 90% of the TCD8s were speciﬁc for site IV (Tatum et al.,
2008). Splenocytes isolated from TCR-IV transgenic mice were
adoptively transferred into groups of 3∼4WTor SV11mice before
immunization with Tag-expressing cells. The percentage of prolif-
erating and apoptotic TCR-IV cells recovered from the recipients
was assessed through in vivo BrdU incorporation assay (Figure 3B)
and Annexin V apoptosis assay (Figure 3C) on days 3 and 4 after
immunization, respectively. These data were subsequently used
to estimate the ratio of proliferation (P ratio – cWT/cTumor) and
apoptosis (A ratio – wWT/wTumor) rates of site IV-speciﬁc TCD8s
in WT to transgenic mice. As shown in Figure 3D, the value of
the proliferation ratio is higher than the apoptosis ratio for both
time points, and the difference is statistically signiﬁcant [P < 0.032
(t = 2.07) at 3 days and P < 0.0001 (t = 4.57) at day 4 after immu-
nization]. Moreover, different trends of change in the frequency
of TCR-IV cells in WT and brain tumor-bearing transgenic mice
FIGURE 3 | Site IV-specificTCD8s have different proliferation and apoptosis
kinetics underWT and tumor conditions. Data was obtained 3 and 4 days
after immunization usingTag-expressing cells. From (A) to (C), each circle
represents data obtained from one mouse, either WT (•) or SV11 (◦).
(A)The percentage of adoptively transferred site IV-speciﬁc TCD8s in total
splenocytes as assessed by ﬂow cytometry. Although not statistically
signiﬁcant, there was an increase of site IV-speciﬁc TCD8s percentage in WT
mice, but a decrease of site IV-speciﬁc TCD8s percentage in SV11. Site
IV-speciﬁc TCD8s was deﬁned as CD8+, Tetramer IV+ (indicating T cells
speciﬁc for epitope IV), and CD90.1+ (indicating T cells derived from the
TCR-IV mouse line). (B)The percentage of proliferating site IV-speciﬁc TCD8s in
total CD8+T cells of WT and SV11 mice after immunization as assessed by
BrdU assay. The proliferation rate remained similar under WT and SV11
condition. (C)The percentage of apoptotic site IV-speciﬁc TCD8s in total CD8+
cells of WT and SV11 mice as assessed by apoptosis assay. Although not
statistically signiﬁcant, there is an increase of apoptotic site IV-speciﬁc TCD8s
percentage in both WT and SV11, with SV11 more so than WT. (D)The WT to
SV11 ratio of percentages of proliferating site IV-speciﬁc TCD8s (P ratio:
proliferation ratio) and the same ratio of percentages of apoptotic site
IV-speciﬁc TCD8s (A ratio: apoptosis ratio) for both time points. Each circle
indicates one possible ratio between WT data and SV11 data at the same time
point, either proliferation ratio (•) or apoptosis ratio (◦). Proliferation ratio is
higher than the apoptosis ratio at day 3 (*P < 0.032, t = 2.07) and day 4
(**P < 0.0001, t = 4.57).
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between days 3 and 4, with a slight increase in TCR-IV T cells
in WT and slight decrease in TCR-IV T cells in transgenic mice
(Figure 3A) suggest that the rate of apoptosis is higher than the
rate of proliferation in the presence of tumors. The results suggest
that the net growth in TCD8s is negative in transgenic mice, while
positive in WT mice, assuming that the proliferation rate of the
TCD8 clones in WT and transgenic mice is in a comparable range.
Next, we discuss the dynamics of site-speciﬁc TCD8s in WT and
transgenic mice.
RESPONSE OF WT MICE TO IMMUNIZATION WITH TAG-TRANSFORMED
CELLS
We used our own experimental data (closed symbols in Figure 4)
and the data from (Mylin et al., 2000; open symbols in Figure 4)
to model the behavior of the TCD8 response to the four H-2b-
restricted Tag determinants following immunization with Tag-
transformed cells inWT mice. Mice were immunized with 5× 107
SV40 Tag-transformed cells and the site-speciﬁc TCD8 response
was analyzed by staining with site-speciﬁc MHC tetramers at the
indicated time points. The simulations of the TCD8 activity were
then ﬁt to the experimental data (Figure 4).
Figure 4 shows that TCD8s speciﬁc for site IV are highest in
numbers followed by TCD8s speciﬁc for site I and then TCD8s
speciﬁc for site II/III. The model can reproduce the observation
that the addition of excess site I-speciﬁc precursor cells reverses
the hierarchy so that the number of TCD8s speciﬁc to site I is
higher than that of site IV-speciﬁc TCD8s (Tatum et al., 2010). This
FIGURE 4 | Simulated (lines) and experimental (symbols)TCD8s in
response to the immunization ofWT mice withTag-transformed cells.
The response of site I-, II/III-, IV-, and V-speciﬁc TCD8s is shown by the solid,
dashed, dash-dot, and dotted lines, respectively. The gray arrows represent
the terms in the mathematical model dominating the dynamics. The data
from Mylin et al. (2000); empty symbols) and current study (ﬁlled symbols)
representing site I (squares), II/III (triangles), and IV (diamonds) speciﬁc
TCD8s is shown.The data from Mylin et al. (2000) is scaled by a multiplicative
factor to minimize the variation between the two experiments. The initial
conditions were, TCD8s= 0, andTag-expressing cells (non-proliferating)= 106.
The parameter values are n = 5× 0.3/1/4 proportion for site V/I/IV
respectively, b = 0.50/day, c = 1.08/day, w I = 0.04/day, w II/III = 0.09/day,
w IV = 0.02/day, wV = 1.02/day, αi = 1E100 cells.
result indicates that the dominance hierarchy, at least among the
three most dominant determinants, is impacted by the precursor
frequency. However, the undetectable numbers of site V-speciﬁc
TCD8s are not explained by a lower precursor frequency but due to
their smallest net growth upon exposure to the antigen. These cells
become detectable upon immunization with mutated Tag express-
ing only site V determinant because of the availability of tumor
cells to drive their proliferation. For the ﬁt shown in Figure 4 at
the peak of the response, the hierarchy of the Tag site-speciﬁc TCD8
response is dependent on the site-speciﬁc activation of new TCD8s
and the apoptosis rates. The proliferation rate (c) is kept the same
for all site-speciﬁc TCD8s since it was not required to be different
to reproduce the observed data in Figure 4.
The TCD8 dynamics can be characterized by an initial linear
conversion of naïve cells into activated TCD8s in response to tumor
cells, followed by exponential growth of the TCD8s. As a result, the
number of tumor cells rapidly decreases toward 0 (not shown). In
simulations, tumor cells are cleared around day 10, which coin-
cides with the experimentally observed time after which minimal
effector TCD8 are proliferating. When tumor cell numbers become
negligible, the contraction phase of TCD8s begin which is dom-
inated by exponential decay (at the rate wi). In this phase, the
relationships between the rates of apoptosis (wi) of site-speciﬁc
TCD8s can be estimated.
TCD8s targeting the dominant site IV and subdominant site
I make up 80% of the Tag-speciﬁc TCD8 response. The model
predicts that the only way to reproduce the highest and most pro-
longed site IV-speciﬁc TCD8 response is to have a lower apoptosis
rate for site IV-speciﬁc TCD8s compared to site I-speciﬁc TCD8s
(w IV <w I). To test this novel prediction of site-speciﬁc apoptosis
rates, we immunized groups of three WT mice by intraperitoneal
injection of C57BL/6-derived Tag-transformed cells. The percent-
age of apoptotic and proliferating TCD8s speciﬁc for site I and
IV was assessed 9 and 14 days after immunization as estimations
of the respective rates of apoptosis and proliferation. In addi-
tion, the percentage of site I-speciﬁc and site IV-speciﬁc TCD8s
in splenocytes was assessed 7, 9, 14, and 23 days after immuniza-
tion. Since the model estimates the relationship between the two
rates of apoptosis when the activation of the TCD8s is minimal, we
tested our prediction after day 14 when no signiﬁcant prolifera-
tion was observed in the experiments (Figure 5A). As shown in
Figure 5B, the percentage of apoptosis for site I-speciﬁc TCD8 was
signiﬁcantly higher than for site IV-speciﬁc TCD8s (P < 0.012). A
differential cell death rate was also reﬂected in Figure 5C, which
showed the percentage of site-speciﬁc TCD8s in splenocytes. While
the percentage of site IV-speciﬁc TCD8s remained consistent after
day 9, there was a drop in the percentage of site I-speciﬁc TCD8s
between day 9 and day 14. Taken together, these results suggest
that site I-speciﬁc TCD8s undergo cell death at a higher average
rate compared to site IV-speciﬁc TCD8s, explaining the prolonged
high level accumulation of site IV-speciﬁc T cells. We note that
the same rates of proliferation for site I- and IV-speciﬁc TCD8s
are used in the model; a parsimonious assumption which is also
supported by Figure 5A. However, day 9 is at the end of the
expansion phase and many parameters in addition to the pro-
liferation rates may play a role in explaining the observations
(Figures 5A,B).
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CD8+ T CELL RESPONSE IN TRANSGENIC MICE
The three Tag-transgenic systems that autonomously develop
tumors vary in the lifespan of the mice, metastasis of the tumors,
responsiveness to immune-therapies and tolerance of TCD8s. The
computer simulations were run to cover the duration of the life
span for each transgenic mouse line. The simulated tumor pheno-
type reproduces the exponential tumor growth and TCD8 expan-
sion during the early period of antigen expression, followed by
an unresponsiveness of TCD8s. The tolerance onset time is differ-
ent for site-speciﬁc TCD8s in different transgenic mouse lines. This
information was used to parameterize the apoptosis rates (Table 1;
Figure A3A in Appendix) and all the other parameters were kept
the same across different tumor models. Figures 6A,B reproduce
the sequential loss (tolerance onset) of site-speciﬁc TCD8s in pan-
creatic tumor (Otahal et al., 2006) and osteosarcoma (Schell et al.,
2000) models, respectively. Tissue speciﬁc death rates for TCD8s
against each site (wi) reproduce the correct tolerance onset in
different transgenic mouse lines. We observed interesting regular-
ities between the rates of apoptosis. For example, the apoptosis
rate of site I-speciﬁc TCD8s is always greater than that of site
IV-speciﬁc TCD8s as seen in the WT model. Thus while the spe-
ciﬁc values of the parameters can be different, the unavoidable
similarities pointed out by our dynamic model can improve our
understanding of the tumor growth and TCD8 response.
Changes in the other parameters including the growth rate of
tumor cells (r) and the rate of TCD8 mediated killing of tumor
cells (b) were not necessary to reproduce any of the observations,
though they could affect the modeled tumor size. The unrespon-
siveness of TCD8s targeting particular determinants was conﬁrmed
by the absence of TCD8 activation after simulating in silico immu-
nization with Tag-expressing cells (modeled by si; Figure 7). In
the brain tumor model (Schell et al., 1999) TCD8s speciﬁc for the
three most dominant Tag sites undergo central tolerance; hence
we only see the TCD8s speciﬁc for the immunorecessive site V
which remain responsive throughout the lifespan of these trans-
genic mice. However, the simulations indicate that the activity of
these TCD8s is lower than in WT mice (Figure 6C).
Next,we used our model to predict the peak of TCD8 accumula-
tion, since tumor treatment is most effective when active TCD8s are
high. The tumor aswell asWTmodels predict that site I TCD8s peak
FIGURE 5 | Site I- and site IV-specificTCD8s have different apoptosis
kinetics after immunization. (A) Percentage of proliferating cells
assessed by BrdU proliferation assay and (B) Annexin V positive cells
indicating apoptotic cells among site I (ﬁlled) and site IV (empty) speciﬁc
TCD8s. The site I-speciﬁc TCD8s undergoing apoptosis are signiﬁcantly higher
than site IV-speciﬁc TCD8s (*P < 0.012). (C) Percentage of site I-speciﬁc
TCD8s () and site IV-speciﬁc TCD8s () among total splenocytes 7, 9, 14,
and 23 days after immunization. Comparing to site IV-speciﬁc TCD8s,
there is a drop in the percentage of site I-speciﬁc TCD8s between days 9
and 14.
Table 1 | Model parameters and description.
Parameter Description Units Average values
(of the non-zero
parameters
used in Figure 6)
Control characteristics
r Proliferation rate of tumor cells 1/day 0.09 Tumor growth
ni Number of TCD8’s activated against site i from naïve
cells
Cells 2.05 Initial growth of TCD8’s speciﬁc for site i
b Killing rate of tumor cells by TCD8’s 1/day 0.5 Tumor decay
c Proliferation rate of TCD8’s 1/day 0.35 Exponential growth of TCD8’s
wi Apoptosis rate of TCD8’s speciﬁc to site i 1/day 0.49 Exponential decay of TCD8’s speciﬁc for
site i
αi Number of tumor cells when the differentiation of
TCD8’s speciﬁc to site i is half of its maximum value
Cells 40.0 Effect ofTumor on linear growth ofTCD8’s
speciﬁc for site i
β Number of tumor cells when the rate of killing by
TCD8’s is half of its maximum
Cells 10.0 Effect of TCD8’s onTumor decay
σ Number of tumor cells whenTCD8’s proliferation is
half of its maximum
Cells 10.0 Effect of Tumor onTCD8’s growth
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FIGURE 6 | SimulatedTCD8s response in (A) pancreatic tumors, (B)
osteosarcomas, and (C) brain tumors.Y -axis depicts the number of TCD8s
in arbitrary units and x -axis depicts the time in days. Site I-speciﬁc TCD8s is
shown with a dashed line, TII/III with a dash-dot line, site IV-speciﬁc TCD8s
with a solid line, andTV with a dot line. Light gray arrows show the average
lifespan of mice. All cases show a sequential loss of TCD8 cells against
different sites. The insets indicate tumor growth.
earlier than site IVTCD8s (Mylin et al., 2000). Inosteosarcomas, site
I-speciﬁc TCD8s reach higher numbers than in pancreatic tumors
(Figure 6B). The peaks in TCD8 accumulation in the osteosar-
coma model occur at later time points (at 18 days for TCD8I and
24 days for TCD8IV) as compared to the peaks of site I-speciﬁc
TCD8s (4th day) and site IV-speciﬁc TCD8s (7th day) in the pan-
creatic model (compare Figures 6A,B). The brain tumor model
(Figure 6C) predicts an earlier peak of site V-speciﬁc TCD8s com-
pared to the osteosarcoma model (days 23 and 30, respectively)
since TCD8s targeting the dominant sites are absent, resulting in
increased availability of antigen. Thus our model can detect the
differences in the timing of the peaks in different models.
In conclusion, the tumor models give insight into the tis-
sue speciﬁcity, for example revealing that osteosarcomas elicit a
stronger response as compared to pancreatic tumors. All tumors
inhibit activation of naïve cells and reduce the net growth of TCD8
cells but differences in the apoptosis rates of the recruited TCD8s
is a critical factor in determining a tissue-speciﬁc response.
FIGURE 7 |The pancreatic tumor shown in Figure 6 is here modified
(b = 3.5, β= 100) and subjected to in silico site IV immunizations of
equal strength on (A) day 35 and (B) day 180. Insets (A,B) show tumor
cells on a log scale. Site I-speciﬁcTCD8s is shown with a dashed line and site
IV-speciﬁc TCD8s with a solid line (TII/III andTV have negligible values). The
early immunization results in a steady state of tumor cells and site
IV-speciﬁc TCD8s, whereas the later immunization fails to signiﬁcantly
inﬂuence tumor growth.
TUMOR CONTROL
Tumors can be controlled by various immune therapies including
immunization with tumor antigen and the adoptive transfer of
immune cells (Hersey, 2010; Moschella et al., 2010; van den Broek
et al., 2010). To gain insight into the mechanisms of tumor control
we simulated a known case of control of pancreatic tumors upon
immunization (Otahal et al., 2006). In this study early immuniza-
tion on day 35 can prevent pancreatic tumor appearance whereas
immunization after day 180 cannot prevent tumor formation.
Our simulations reproduce this behavior. Simulated immuniza-
tion leads to a sharp increase in site IV-speciﬁc TCD8s above the
endogenous levels, followed by a decrease that correlates with a
drop in tumor cells. Experimentally it is expected that the TCD8
response upon immunization surpasses the response generated
against the endogenous tumor. Thus the model could simulate
the effect of early and late immunization in case of pancreatic
tumors.
However, in transgenic mice Tag-expressing cells persist in
lower numbers in case of early immunization so that the pan-
creatic functions are not disrupted. To reproduce this observation
the rate of TCD8 proliferation, the maximal rate of TCD8 mediated
www.frontiersin.org July 2011 | Volume 2 | Article 32 | 9
Campbell et al. Quantitative study of tumor pathogenesis
killing of tumor cells, and the threshold number of tumor cells
that inhibit killing have to be increased. After increasing these
parameters the dose of immunization could be decreased and the
control of tumors with early immunization (Figure 7A) but not
late immunization (Figure 7B) was reproduced in the pancreatic
tumors (Figure 7, inset). Thus our model suggests that exposure
to external antigen in transgenic mice facilitates the detection of
tumor cells by TCD8s and the immunogenicity of Tag.
DISCUSSION
The current work sheds light upon mechanisms that determine
TCD8 tolerance onset and the characteristics leading to the site-
speciﬁc TCD8s response. Both the dynamic model and the exper-
imental data show that the apoptosis rates of TCD8 clones are
context dependent and that the response in WT C57BL/6 mice is
quantitatively stronger than the response in Tag-transgenic mice.
This weaker response in Tag-transgenic mice aids the establish-
ment of tolerance in the presence of progressing tumors. We
hypothesize that the weaker response is driven by the immediate
encounter of the peripheral T cells to Tag expressed on the tumor
leading to undetectable TCD8 numbers in the transgenic mice.
Figure 3 supports this hypothesis by showing a higher apoptotic
population in tumor-bearing mice. In fact, in SV11 mice trans-
ferred cells encounter tumor antigen earlier than Tag from the cells
used for immunization, suggesting that an early encounterwith the
endogenous tumor antigen also limits response to the exogenous
antigen (Ryan and Schell, 2006). In the case of natural tumors, it
is possible that the net growth of TCD8s varies over the course
of tumor progression. The accumulation of responsive TCD8s
can be enhanced by using anti-CD40 or anti-CTLA-4 antibodies
(Otahal et al., 2007; Ryan et al., 2008). The tissue-speciﬁc differ-
ences in the peaks of the TCD8 responsewill affect the time atwhich
immune therapy will be most effective. Differential expression of
negative regulators of the receptors such as PD-L1 and Tim3 lig-
and within tumors of distinct tissues might lead to tissue-speciﬁc
apoptosis.
Though TCD8 tolerance is often observed, particularly in the
setting of cancer or transgene expression, the mechanisms leading
to tolerance are not clear. Factors that have received considerable
attention are the density of peptide/MHC-I complexes, the afﬁn-
ity of TCR for peptide/MHC complexes and the avidity of the
interaction between T cells and antigen-presenting cells (Abbas
et al., 2004). These factors affect the activation of TCD8s and their
effects on the TCD8 response are modeled indirectly by assuming
high-dose inhibition, antigen-induced cell death (Kabelitz et al.,
1993), and immune suppression. While we also include satura-
tion of TCD8s in response to large tumors (Graw and Regoes,
2009), we compare the rate of activation and apoptosis in dis-
tinct mice in which tolerance is either observed or not. Although
experimentally it is difﬁcult to measure the densities of peptide-
MHCI complexes and afﬁnities of TCR, our approach allows us to
establish relationships between different parameters and test them
experimentally. Moreover, our model suggests that the differen-
tiation of naïve T cells is also affected during tolerance. Various
evidence such as the disruption of MHCI-peptide and TCR com-
plex (Nagaraj et al., 2007), TCD8 exhaustion (Moskophidis et al.,
1993) and tumor-induced TCD8 suppressive microenvironment
(Lee et al., 1999; Khong and Restifo, 2002) support the inhibition
of the differentiation from naïve T cells during tolerance. Studies
of the TCD8 response to the Tag determinants suggest that toler-
ance is related to immunodominance since TCD8 speciﬁc for the
immunorecessive determinant (siteV) are the least sensitive to tol-
erance even in the highly tolerogenic brain tumor model (Schell
et al., 2000). In this context, it is interesting that subdominant
site I-speciﬁc TCD8s undergo tolerance earlier than immunodom-
inant site IV-speciﬁc TCD8s, suggesting that higher levels of site
I/MHC versus site IV/MHC complexes may be achieved in vivo
during tumor progression. We assume that the dependence of
the T cell response on the number of tumor cells is described by
Michaelis–Menten kinetics which is a commonly used functional
form to model saturating response at high doses in biological
systems. The support for such behavior comes from observa-
tions in chronic infections and cancers which limit the activation
of the immune responses even when the antigen is not cleared
(Kabelitz et al., 1993; Wigginton and Kirschner, 2001). We note
that the Michaelis–Menten function is a special case of a Hill
function which may also be a good choice but it has an addi-
tional unknown parameter as compared to the Michaelis–Menten
function.
Simulations in WT mice suggest that the differential activities
of site-speciﬁc TCD8s are driven by the site-speciﬁc rates of apop-
tosis. The rate of apoptosis was estimated in the contraction phase
when Tag-expressing cells are cleared. At earlier time points the
percentages observed in the experiments (Figures 3C and 6B) are
the outcome of the dynamics modeled by the rate of activation
(n), proliferation (c), and apoptosis (wi). In the absence of exper-
imental estimates the rate constants used in our model represent
an average rate of apoptosis over time. Hence we validate model-
predicted inequalities rather than attempting to estimate the exact
values of apoptosis rates. Though free decay is a commonly made
assumption in dynamic models, antigen concentrations and the
duration of antigen exposure can affect the apoptosis rate of
the TCD8 cells which can be included in a future extension of
the current model (Porter and Harty, 2006). On the contrary, the
accurate prediction of the rate of proliferation (c) was not pos-
sible (Figure 4) due to the sparse data (Trinchieri et al., 1976)
and various parameters affecting the expansion phase including
TCD8 apoptosis (wi; Figure 5B), differentiation from naïve T cells
(ni), and the proliferation of TCD8s (c). The use of similar pro-
liferation rates for TCD8s speciﬁc to site I and IV is supported by
the experimental data (Figure 5A). We maintain the same rate of
proliferation for all site-speciﬁc TCD8s, a simpliﬁcation which we
believe is valid for the dominant sites. The rules may be differ-
ent for site V since the addition of more site V-speciﬁc precursors
does not overcome theweak response to siteV (Otahal et al., 2005).
However, estimating the true proliferation rate of site V-speciﬁc
TCD8s is challenging since these cells remain below the thresh-
old of detection following immunization of WT mice with Tag.
Overall the data support a mechanism in which differences in the
rate of apoptosis explain the prolonged high level accumulation
of site IV-speciﬁc TCD8s cells relative to TCD8s responding to the
subdominant determinants.
The current model is an outcome of a step-wise process to
reproduce the TCD8 response in WT and Tag-transgenic mice.
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As a ﬁrst step we modeled all the immune processes that are
hypothesized to be important in TCD8 activation. Next, we
reduced the model based on what is required to reproduce the
known experimental observations, for example separately mod-
eling pMHC complexes on the antigen-presenting cells did not
lead to an improvement of the model but increased the number of
unknown parameters (Handel andAntia, 2008).We do not explic-
itly include naïve TCD8s in the model, assuming that they are not a
rate limiting factor in the tumor-induced T cell interactions. How-
ever, in the biologically accepted range of parameters (Figure A3
in Appendix) the effective value of the rate of differentiation of
precursor cells is never unlimited in our model. Many mathemat-
ical models have assumed a constant number of precursor cells
and in those models estimates of the effective rate of thymic pro-
duction vary within 25% of the nic values used in our model. The
mathematical formulations modeling TCD8 response to tumors
generally incorporate higher values of the source for TCD8s com-
pared to the models of TCD8 response to viruses. This could be
because the immune response is measured following immuniza-
tion which usually inﬂates the response. We also would like to
note that the value of the rate of proliferation is also in the range
of estimations by other studies (De Boer et al., 2003; Bocharov
et al., 2004).
In the current model we did not explore the possibility of intro-
ducing competition between TCD8 clones because recent results
indicate that in WT mice competition between the endogenous
TCD8s responding to sites I and IV does not play a signiﬁcant role
in limiting the magnitude of the T cell response (Tatum et al.,
2010). We did previously observe that the presence of the dom-
inant Tag determinants can limit the response to site V (Mylin
et al., 2000). The absence of a detectable endogenous site V-
speciﬁc TCD8 response upon immunization with Tag-expressing
cells makes it difﬁcult to make assumptions about the interactions
between physiological levels of TCD8s speciﬁc for dominant and
recessive epitopes. Though we cannot rule out the possibility of
competitive interactions, non-competitive interactions mediated
by weak engagement of TCR with site V-MHCI complexes can
also drive the immunorecessive response as modeled in the cur-
rent study. In conclusion, the mathematical model presented here
is one of the few attempts to characterize in vivo TCD8 responses to
known autochthonous tumors and it systematically analyzes the
expansion and contraction phases during the TCD8 response to a
known tumor antigen.
In the future, this model could be expanded by including com-
petitive interactions between site-speciﬁc clones for different anti-
gens andby separatelymodeling the reactivationof memoryT cells
in response to the antigen (Camus and Galon, 2010). Modeling of
naïveT cells as a separate entitywill also allowus to study the effects
of adoptive transfers, which are currently under clinical investiga-
tion for several cancer types. One could also incorporate immune
cells such as T regulatory cells which are implicated in inducing
tolerance andmodel the recovery of responsive TCD8 cells (Sharabi
and Ghera, 2010). Moreover, the case of uncontrolled T cell and
Tag-expressing cell growth is similar to autoimmune response and
though it is not a focus of the current study, the model can be
used to study the relationship between tumor and autoimmunity
since tolerance (Schuetz et al., 2010) and dysregulation of immune
responses (Reeves et al., 2009) are implicated in both diseases.
While opportunities exist to build on this basic model, relevant
in vivo data are needed to inform and parameterize the expan-
sion. Moreover, standardization of experimental techniques will
be useful since the observations are not only affected by personal
and lab-speciﬁc factors but also by the mice strains used. We show
here that ourmodel not only provides novel predictions that canbe
experimentally validated but also gives important insights based
on sparse data. Models such as ours will be increasingly devel-
oped and used to provide novel predictions and biological under-
standing of the complex interaction between the immune system
and cancer.
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APPENDIX
THE EFFECT OF VARIATION OF THE PARAMETERS ON THE RATE OF
KILLING OF TUMOR CELLS BY TCD8s
Nullcline Analysis
In this section we elaborate upon the biologically relevant dynam-
ical regimes exhibited by the model. While we show the evolution
of the number of tumor cells and TCD8 cells as a function of time
in Figure A2, we here show the two variables plotted against one
another. This method allows for straightforward identiﬁcation of
the system dynamics for any possible number of TCD8s and tumor
cells.
The directional ﬁeld, which is represented by gray arrows in the
lower panels of Figure A2, indicates the evolution of tumor cells
andTCD8swith time. For instance,when the number of tumor cells
and TCD8s are in an area of phase space where the directional ﬁeld
is increasing in both dimensions, the number of Tag-expressing
cells and TCD8s cells will both increase for a small advancement
in time, and their next position in phase space will decide the
change in both variables for the next advancement in time. The
trajectory is shown by the solid black line. Broken black lines show
the boundary between areas in phase space that are increasing or
decreasing with respect to TCD8s (dash-dotted line) or tumor cells
(dashed line). The intersection of nullclines corresponds to steady
states of the system. Zero tumor cells and TCD8s is always a steady
state; for the parameters investigated here, the nullclines typically
admit at most one additional steady state (see main text for the
mathematical form of the nullclines).
The clearance scenario (Figure A2A) shows the system’s start-
ing point in a location where the directional ﬁeld is increasing
in both dimensions. The trajectory crosses the tumor cell null-
cline, whereupon the number of tumor cells begins decreasing.
Once it drops below the TCD8 nullcline, the number of TCD8s
also begins decreasing; the system eventually reaches a steady state
FIGUREA1 |The effect of the variation in the rate constant and the
number of tumor cells on theTCD8 mediated killing ofTag-expressing
cells.The inset shows the effect of tumor cell numbers on the activation of
TCD8s.
located very close to 0 tumor cells and TCD8s. The different para-
meters used in Figures 2B–E alter the properties of the directional
ﬁeld and nullclines, and so inﬂuence the evolution of the sys-
tem despite the fact that they start in the same location in phase
space.
Parameter values and their sensitivity
There are a maximum of 18 parameters in the model. For sim-
plicity the parameters are assumed to have the same value in
different tissues in the absence of tissue-speciﬁc information to
constrain the values. However, site-speciﬁc apoptosis rates were
implemented to reproduce the different onset times of tolerance
of site-speciﬁc TCD8s. To study the effect of parameters we sys-
tematically varied the parameter values from 50 to 200% of their
initial values [i.e., pi = kp0, k ∈ (0.5,2)]. We calculated the percent
deviation due to a given parameter modiﬁcation for variable V at
time τ as
dv(t=τ) =
∣∣∣∣V (p = p0, t = τ) − V (p = pi , t = τ)V (p = p0, t = τ)
∣∣∣∣
Averaging over all time points gives an average percent deviation
(APD) for variable V and deviation k for parameter p.
In the model, the peak of the TCD8 accumulation corresponds
to the system crossing the TCD8 nullcline in phase space (see main
text). Themain parameters that drive the response of the TCD8s are
c and wi. We modify these parameters and quantify the difference
of the ensuing dynamics from the original via an APD. There are a
maximum of 18 parameters in the model and the parameters are
assumed to have the same value in different tissues for simplicity in
the absence of tissue-speciﬁc information to constrain the values.
However, site-speciﬁc activation of naïve cells and apoptosis rates
were implemented to reproduce the onset times of tolerance. To
study the effect of parameters we systematically varied the para-
meter values from 50 to 200% of their initial values (i.e., pi = kp0,
k ∈ (0.5,2)). We calculated the percent deviation due to a given
parameter modiﬁcation for variable V at time τ as
dv(t=τ) =
∣∣∣∣V (p = p0, t = τ) − V (p = pi , t = τ)V (p = p0, t = τ)
∣∣∣∣
Averaging over all time points gives an APD for variable V and
deviation k for parameter p.
This measure identiﬁes at a glance the sensitivity of the system
to variations in particular parameters. We show as an illustrative
example the APDs for the pancreatic, osteosarcoma, and WT cases
(Figures A3B–D). Reducing wIV in a tumor case serves to bolster
the immune response; T IV effectively chases after IC more vigor-
ously before giving up, until eventually it is able to clear the tumor
entirely. In the pancreatic case (Figure A3B), w is not decreased
enough to show the regime clearance. In the osteosarcoma case,
the full transition is seen. In the case of brain tumors, T IV plays
a minimal role; varying w IV has comparatively little effect on the
system dynamics.
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FIGUREA2 |The behaviors from Figure A1 are shown in phase space. Light gray arrows indicate the directional ﬁeld, and the nullclines indicate boundaries
between positive and negative horizontal or vertical components of the directional ﬁeld. Intersections of the nullclines indicate steady states of the system.
FIGUREA3 | (A)The values of the parameters that were varied in different
cases are shown on the x -axis for the wild-type (black squares), pancreatic
tumor (black diamonds), osteosarcoma (white squares), and brain tumor
(white diamonds) models. nI ﬁxes the value of nIV(= 4nI ) and nV (= 0.3nI ), and
are not shown. (B–D)The effect of varying the w IV parameters by a
multiplicative factor (x -axes) on the variables is shown as an average percent
deviation (APD) in the pancreatic, osteosarcoma, and wild-type cases
(y -axes). Very small APDs (<10−9) are not shown.
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